Person walking on a path, symbolizing diabetes management journey.

Decoding Diabetes: Are You Reaching Your Health Goals?

Nico Varela monogram
Nico Varela in Health & Wellness October 2026 • 4 min read.

"A new study from Dubai sheds light on how well people with diabetes are managing their condition, highlighting the need for personalized care and better strategies."


Diabetes is a global health challenge, and managing it effectively is crucial for preventing serious complications. While advancements in medicine and technology offer hope, understanding how well people are actually controlling their diabetes is essential.

A recent study conducted in Dubai, United Arab Emirates, examined the glycemic and lipid control in patients with diabetes and cardiovascular or renal diseases. This research provides valuable insights into the current state of diabetes management and highlights areas where improvements are needed.

This article will break down the key findings of the Dubai study, explore what these results mean for people living with diabetes, and discuss strategies for achieving better health outcomes.

AI Search Multiple angles on this topic

The Scale of Diabetes

The CDC estimates that 40.1 million people in the United States had diagnosed or undiagnosed diabetes in 2023, representing 12.0% of the population. Globally, the World Health Organization reports that 14% of adults aged 18 and older were living with diabetes in 2022, up from 7% in 1990. Poor glycemic control remains a major concern: a 2022 review found prevalence ranging from 45.2% to 93% across the studies it examined.

Monitoring and Glycemic Targets

Standard diabetes care uses glucose monitoring, medication, and individualized glycemic targets. The 2025 pharmacologic treatment guidance reports that integrating continuous glucose monitoring (CGM) soon after diagnosis improves glycemic outcomes and decreases hypoglycemic events. CGM is described as a standard glucose-monitoring method for most people with type 1 diabetes, while one treatment reference identifies premeal glucose of 90–130 mg/dL and HbA1c below 7% as ideal targets. These approaches still require clinical judgment because treatment goals and methods must be matched to the individual.

From Pancreas Research to Insulin

Diabetes was mentioned in Egyptian medical papyri dating to approximately 1500 BCE, according to a history published by Diabetes Research Connection. In 1889, Oskar Minkowski and Joseph von Mering removed a dog's pancreas and produced severe, fatal diabetes, an experiment that helped establish the pancreas's central role in the disease. The discovery of insulin in 1921 revolutionized the management of type 1 diabetes, and 2021 marked its centenary.

The Dubai Diabetes Study: Key Findings

Person walking on a path, symbolizing diabetes management journey.

The study analyzed data from over 26,000 patients in Dubai, focusing on those with type 1 and type 2 diabetes who also had cardiovascular or kidney disease. Researchers looked at how well these patients were meeting target goals for blood sugar (HbA1c) and cholesterol (LDL and non-HDL).

Here's a summary of the key findings:

  • Suboptimal Control: Many patients weren't meeting recommended targets for blood sugar and cholesterol.
  • Positive Trend: There was a gradual improvement in both blood sugar and cholesterol control over the five years of the study.
  • Type 1 vs. Type 2: People with type 2 diabetes generally had better blood sugar control than those with type 1 diabetes.
  • LDL Cholesterol: About a third of patients achieved the target LDL cholesterol level of below 70 mg/dl.
  • Non-HDL Cholesterol: There was a numerical improvement in non-HDL cholesterol levels over time, but it wasn't statistically significant.
  • Consistent Complication Rates: The number of patients with diabetes-related complications remained relatively stable throughout the study period.
AI Search Multiple angles on this topic

Expanding Diabetes Management

Recent reviews examine advances in type 2 diabetes management across both drug and non-drug treatments. The CDC reports that participation in diabetes self-management education and support can improve glycemic control, blood pressure and cholesterol management, medication adherence, nutrition, and physical activity. A 2022 consensus report also identifies physical activity as an essential component of type 2 diabetes management because it improves glycemic control. Together, these sources frame diabetes care as broader than medication alone.

Why Control Remains Difficult

Diabetes management is complex, and several common mistakes can occur in daily clinical practice, according to a 2024 review. Poor glycemic control and poor medication adherence are influenced by many factors, including what one source describes as a lack of integrated care. The consequences extend beyond laboratory measurements: diabetes complications can affect morbidity, mortality, quality of life, and health costs. These findings challenge the idea that prescribing treatment alone reliably produces successful long-term management.

CGM Compared With Conventional Monitoring

In adults with type 2 diabetes using basal insulin plus modern therapies, real-time CGM improved glycemic control compared with self-monitoring of blood glucose during both self-management and clinician-supported care. A separate review reports that remote glucose monitoring has significant potential to improve glycemic control and specific lipid parameters, although it calls for standardized protocols and further research. CGM systems are offered by major competitors including Medtronic, Dexcom, FreeStyle, and Eversense. International consensus also recommends specific CGM-derived targets, including time spent in defined glucose ranges, to assess therapy.

These findings suggest that while there's progress in diabetes management, many individuals still struggle to reach their health goals. The study also highlights the importance of individualized care, as different types of diabetes may require tailored approaches.

Taking Control of Your Diabetes: A Path Forward

The Dubai study underscores the need for a renewed focus on helping people with diabetes achieve their health goals. This requires a multi-faceted approach that includes:

AI Search Multiple angles on this topic

Toward Integrated CGM Care

Recent expert work is focused on how continuous glucose monitoring should be integrated into outpatient diabetes care. One 2025 consensus effort develops country-specific recommendations for CGM integration in Iran, while another expert opinion statement evaluates real-time CGM for people with type 2 diabetes and provides region-specific guidance. A separate consensus addresses glycemic management in critically ill patients, aiming to provide practical guidance and reference opinions. These sources indicate that CGM recommendations are being adapted to both clinical setting and regional context.

Digital Diabetes Growth

Digital tools are expected to become a larger part of diabetes management. One market forecast projects that the diabetes management apps market will grow from USD 2.09 billion in 2026 to USD 4.38 billion by 2035. Another forecast values the digital diabetes management market at $14.4 billion in 2025 and projects growth from $15.5 billion in 2026 to $29.7 billion by 2033. Glooko's 2026 industry outlook likewise focuses on the evolution of diabetes care and glycemic management, while other research discussions highlight innovative treatments and prevention strategies.

The Daily Work of Management

Diabetes management requires ongoing awareness of the factors that make blood glucose rise and fall. The Mayo Clinic emphasizes that people need to understand these day-to-day influences and how to control them. This perspective places management within everyday routines rather than limiting it to appointments or isolated glucose readings. It also highlights why sustaining health goals requires attention to daily behavior and changing circumstances.

CGM in Real-World Care

Real-world evidence suggests that initiating continuous glucose monitoring can significantly improve glycemic control. A 2025 study reported that its findings were comparable with published real-world studies showing significant improvement after CGM initiation. A separate clinical discussion examines a real-world CGM case study and considers its clinical impact on diabetes management. These sources connect CGM research with the practical experiences of patients and clinicians.

<ul><li><b>Personalized Care:</b> Tailoring treatment plans to individual needs, considering the type of diabetes, presence of complications, and lifestyle factors.</li><li><b>Aggressive Risk Factor Reduction:</b> Focusing on lowering cholesterol and blood pressure in addition to blood sugar control.</li><li><b>Regular Monitoring and Audits:</b> Tracking progress and identifying areas where interventions are needed.</li><li><b>Collaboration:</b> Encouraging communication and teamwork among healthcare providers and patients.</li></ul>

By addressing these challenges and embracing a more proactive approach, we can empower individuals with diabetes to live healthier, longer lives.

What the target results do-and do not-show

Target attainment improved within each group, but the comparison does not show an added advantage for genetic counselling over control at the reported follow-up.[1]

The evidence on intensive glucose lowering does not point to a single benefit across all outcomes: prior findings include microvascular benefit, while a review found increased risk of severe hypoglycaemia. The balance depends on which outcome is being considered.[2] [3]

What remains uncertain about tighter control

  • Would the improvement in target attainment between baseline and follow-up persist over a longer period, and would it translate into clinical outcomes? The reported comparison covers target attainment at follow-up, not those longer-term consequences.[1]
  • How should subgroup comparisons be interpreted when many baseline characteristics are examined? The source cautions that chance differences can arise when a sample is divided into groups, underscoring the need to account for the number of subgroup factors.[4] [5]

Sources

  1. A randomized clinical trial of genetic testing and personalized risk counselling in patients with type 2 diabetes receiving integrated care -The genetic testing and patient empowerment (GEM) trial. (pubmed.ncbi.nlm.nih.gov)
  2. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials (pmc.ncbi.nlm.nih.gov)
  3. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials (pmc.ncbi.nlm.nih.gov)
  4. Effect of Intensive Compared With Standard Glycemia Treatment Strategies on Mortality by Baseline Subgroup Characteristics (pmc.ncbi.nlm.nih.gov)
  5. Point: Intensive Glycemic Control and Mortality in ACCORD—A Chance Finding? (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What were the main findings regarding blood sugar and cholesterol control in the Dubai diabetes study?

The Dubai study revealed that many individuals with diabetes, particularly those with cardiovascular or kidney disease, struggle to maintain optimal blood sugar (HbA1c) and cholesterol (LDL and non-HDL) levels. While there's been a positive trend in glycemic and lipid control over time, a significant portion of patients haven't reached the recommended target goals. Specifically, those with type 2 diabetes showed better blood sugar control than those with type 1 diabetes, and only about one-third achieved the target LDL cholesterol level. It also showed consistent complication rates.

2

Besides blood sugar and cholesterol, what other important factors weren't evaluated in the Dubai study?

The Dubai study primarily focused on blood sugar control (HbA1c) and cholesterol levels (LDL and non-HDL) in patients with both diabetes and cardiovascular or renal diseases. HbA1c reflects average blood sugar levels over the past two to three months, while LDL and non-HDL cholesterol are key indicators of cardiovascular risk. The study aimed to assess how well these markers were being managed in this specific patient population, but did not focus on other vital signs, medication adherence or patient lifestyle choices.

3

Did the Dubai study find any difference in blood sugar control between people with type 1 and type 2 diabetes?

Yes, the Dubai study found that people with type 2 diabetes generally exhibited better blood sugar control compared to those with type 1 diabetes. This difference could be attributed to various factors, including the nature of each diabetes type, treatment approaches, and individual patient characteristics. Type 1 diabetes is an autoimmune condition where the body doesn't produce insulin, making blood sugar management more complex. Type 2 diabetes, often associated with lifestyle factors, may be managed through diet, exercise, and medication.

4

Did the Dubai study show any improvement in diabetes management over time?

The Dubai study indicated a gradual improvement in both blood sugar and cholesterol control over the five-year study period. This positive trend suggests that ongoing efforts in diabetes management, such as advancements in medication, education, and healthcare practices, are having a beneficial impact. However, the study also highlights that there is still room for improvement to achieve optimal health outcomes for all individuals with diabetes, as many patients have not yet reached the recommended targets.

5

What does the Dubai study suggest about personalizing diabetes care?

The Dubai study underscores the critical need for personalized care and tailored approaches in diabetes management. Since individuals with different types of diabetes (type 1 vs. type 2) and varying health conditions (cardiovascular or renal diseases) may require different strategies to achieve their health goals, healthcare providers should consider each patient's unique needs and circumstances. This might involve customized treatment plans, lifestyle modifications, and ongoing monitoring to optimize blood sugar and cholesterol control.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.